Vir Advances HBV, Flu Programs While Focused On COVID-19

Company Brought In Significant Cash Before And After Its IPO

 
• By Mandy Jackson
  
Hepatitis B
Vir has multiple COVID-19 programs, but its lead asset is for hepatitis B • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anti-infective

More from Therapeutic Category